Houston, TX, March 18, 2021 - Audubon Bioscience partners with CTOAM (Cancer Treatment Options and Management). The strategic collaboration will focus on joining forces in raising precision medicine awareness among doctors and patients.
Cancer Treatment Options and Management (CTOAM) is a Canadian-based personalized cancer research and advocacy service that connects cancer patients and their oncologists with the newest advancements in personalized cancer care and precision oncology.
“Thanks to the work that Audubon is doing, science will be able to develop new targeted therapies, immunotherapies, and numerous other treatment options and diagnostics much more rapidly,” said Michelle Morand, Co-founder and Managing Partner at CTOAM. “With all of the advancements we’ve seen in cancer care this last decade, the question isn’t ‘if’ cancer will cease to be a deadly disease, but ‘when.’ The team at Audubon plays an important role in making this dream a reality as quickly as possible. This capability makes us here at CTOAM want to help them in any way we can.”
The partnership will revolve around raising awareness and educating doctors and patients about the value of precision medicine and innovative diagnostic methods such as liquid biopsy tests.
“Our companies are united by the ultimate goal of making cancer a curable disease for everyone. CTOAM is an expert in providing cancer patients with the best personalized treatment approach for their condition, and we are thrilled to partner with them,” said Rostyslav Semikov, CEO of Audubon Bioscience.
This move is part of Audubon’s strategy to work alongside global experts to educate doctors and patients on the importance of precision oncology.
To inquire more information or a comment from our top-management, please contact our PR department at firstname.lastname@example.org.
To learn more about Audubon Bioscience’s service offering, click here.